Lv Xing, Zhao Heng, Niu Xiaona, Wu Yunfu, Wang Mingming, Chen Jie, Song Liqiang
Department of Pulmonary and Critical Care Medicine, Xijing Hospital, Air Force Medical University, Xi'an, China.
Department of Cardiology, Tangdu Hospital, Air Force Medical University, Xi'an, China.
J Thorac Dis. 2024 Oct 31;16(10):6983-6998. doi: 10.21037/jtd-24-1351. Epub 2024 Oct 15.
Reducing mortality among those infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a critical challenge in clinic. The objective of this study was to analyze the effect of the coronavirus disease 2019 (COVID-19) vaccine on the prognosis of individuals infected with the Delta variant of SARS-CoV-2.
In a single-center, retrospective cohort study, all adult patients with COVID-19 from designated hospital in Xi'an, China, during the Delta outbreak from December 2021 to January 2022 were enrolled. The patients were divided into two groups according to whether they received the COVID-19 vaccine, and differences in clinical outcomes (pneumonia, oxygen therapy, severe disease, and mechanical ventilation or death), symptoms, and nucleic acid-negative time between the two groups were compared.
A total of 651 adult patients with COVID-19 were included, among whom 578 were vaccinated and 73 were not vaccinated. Compared with the unvaccinated group, the vaccinated group had lower rates of pneumonia (49.8% 67.1%; P=0.005), oxygen therapy (20.9% 57.5%; P<0.001), severe illness (1.6% 26.0%; P<0.001), and mechanical ventilation or mortality (0.3% 13.7%; P<0.001). Multivariate logistic regression analysis showed that COVID-19 vaccination significantly reduced the risk of requiring oxygen therapy, severe illness, and mechanical ventilation or death. Compared with the unvaccinated group, the vaccinated group had a higher incidence of sore throat (31.8% 17.8%; P=0.01) and a lower incidence of shortness of breath (3.1% 20.5%; P<0.001), diarrhea (1.2% 5.5%; P=0.03), and nausea or vomiting (1.4% 6.8%; P=0.007). The median time of nucleic acid transition to negative was 14.0 [interquartile range (IQR), 10.0-17.0] and 15.0 (IQR, 11.0-18.0) days (P=0.18) in the vaccinated and unvaccinated groups, respectively.
Vaccination may reduce the risk of oxygen therapy, severe illness, and mechanical ventilation or death in patients with Delta variant COVID-19, as well as the incidence of pneumonia. Vaccinated patients had a higher incidence of sore throat and a lower incidence of shortness of breath, diarrhea, and nausea or vomiting compared to nonvaccinated patients. Vaccination did not shorten the time for the emergence of nucleic acid-negative status.
降低严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染者的死亡率仍然是临床上的一项关键挑战。本研究的目的是分析2019冠状病毒病(COVID-19)疫苗对感染SARS-CoV-2 Delta变异株个体预后的影响。
在一项单中心回顾性队列研究中,纳入了2021年12月至2022年1月Delta毒株疫情期间中国西安某指定医院的所有成年COVID-19患者。根据是否接种COVID-19疫苗将患者分为两组,比较两组的临床结局(肺炎、氧疗、重症和机械通气或死亡)、症状以及核酸转阴时间的差异。
共纳入651例成年COVID-19患者,其中578例接种了疫苗,73例未接种疫苗。与未接种疫苗组相比,接种疫苗组的肺炎发生率(49.8%对67.1%;P=0.005)、氧疗发生率(20.9%对57.5%;P<0.001)、重症发生率(1.6%对26.0%;P<0.001)以及机械通气或死亡率(0.3%对13.7%;P<0.001)较低。多因素logistic回归分析显示,接种COVID-19疫苗显著降低了需要氧疗、重症以及机械通气或死亡的风险。与未接种疫苗组相比,接种疫苗组的咽痛发生率较高(31.8%对17.8%;P=0.01),而气短发生率(3.1%对20.5%;P<0.001)、腹泻发生率(1.2%对5.5%;P=0.03)以及恶心或呕吐发生率(1.4%对6.8%;P=0.007)较低。接种疫苗组和未接种疫苗组核酸转阴的中位时间分别为14.0[四分位间距(IQR),10.0-17.0]天和15.0(IQR,11.0-18.0)天(P=0.18)。
接种疫苗可能降低Delta变异株COVID-19患者的氧疗、重症以及机械通气或死亡风险,以及肺炎发生率。与未接种疫苗的患者相比,接种疫苗的患者咽痛发生率较高,而气短、腹泻以及恶心或呕吐的发生率较低。接种疫苗并未缩短核酸转阴的时间。